What was Polivy’s progression-free survival (PFS) vs other treatments?
Polivy (polatuzumab vedotin) is used in combination regimens for certain types of diffuse large B-cell lymphoma (DLBCL). In the pivotal setting where Polivy was compared against chemotherapy plus placebo, the key reported difference was that Polivy’s combination produced a longer progression-free survival than the control regimen.
However, the provided information does not include the specific PFS percentages and the exact comparison arms needed to quantify “how it compares” versus each alternative therapy (such as R-CHP vs R-CHOP, other antibody-drug conjugates, or CAR-T options, depending on line of therapy). Because PFS varies by study design, patient population, and treatment line, the fairest comparison requires the exact trial and comparator regimens.
Which comparison trials and regimens should you look at for PFS?
To compare Polivy PFS to other treatments accurately, you typically need:
- the exact lymphoma subtype (e.g., DLBCL not otherwise specified, high-grade B-cell lymphoma, etc.)
- the treatment line (first-line vs relapsed/refractory)
- the backbone chemotherapy used with Polivy (and what was used in the control arm)
- the trial’s PFS endpoint definition (median PFS and/or PFS rate at a specific time point)
If you share the trial context you mean (for example, “relapsed/refractory DLBCL” and which backbone chemotherapy), I can map Polivy’s PFS result to the specific other regimens from that same study.
How do PFS comparisons differ across first-line vs relapsed/refractory settings?
PFS comparisons can flip depending on setting:
- In relapsed/refractory disease, newer options (including cellular therapies) may show different survival dynamics than standard chemoimmunotherapy combinations.
- In first-line settings, Polivy-type comparisons (when used) are usually measured against established chemoimmunotherapy regimens with different expected baselines.
So “Polivy vs other treatments” is not one single number; it depends on which line of therapy and which comparator regimen you’re using.
If you want, I can compute the exact PFS comparison—what details are missing?
Send any one of these and I’ll produce a direct PFS comparison (with Polivy vs each comparator’s reported PFS rate/median):
- the clinical trial name/number you’re using, or
- the exact treatment pairs (e.g., “Polivy + [chemo] vs placebo + [chemo]”), or
- the disease setting (DLBCL relapsed/refractory or other).
Sources are limited in the information provided here, so I can’t safely quote PFS rates for Polivy versus each alternative without the missing trial/comparator details.